Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases.


Journal

The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362

Informations de publication

Date de publication:
14 07 2022
Historique:
received: 09 11 2021
pubmed: 6 5 2022
medline: 19 7 2022
entrez: 5 5 2022
Statut: ppublish

Résumé

Ectopic acromegaly is a consequence of rare neuroendocrine tumors (NETs) that secrete GHRH. This abnormal GHRH secretion drives GH and IGF-1 excess, with a clinical presentation similar to classical pituitary acromegaly. Identifying the underlying cause for the GH hypersecretion in the setting of ectopic GHRH excess is, however, essential for proper management both of acromegaly and the NET. Owing to the rarity of NETs, the imaging characteristics of the pituitary in ectopic acromegaly have not been analyzed in depth in a large series. Characterize pituitary magnetic resonance imaging (MRI) features at baseline and after NET treatment in patients with ectopic acromegaly. Multicenter, international, retrospective. Tertiary referral pituitary centers. Thirty ectopic acromegaly patients having GHRH hypersecretion. None. MRI characteristics of pituitary gland, particularly T2-weighted signal. In 30 patients with ectopic GHRH-induced acromegaly, we found that most patients had hyperplastic pituitaries. Hyperplasia was usually moderate but was occasionally subtle, with only small volume increases compared with normal ranges for age and sex. T2-weighted signal was hypointense in most patients, especially in those with hyperplastic pituitaries. After treatment of the NET, pituitary size diminished and T2-weighted signal tended to normalize. This comprehensive study of pituitary MRI characteristics in ectopic acromegaly underlines the utility of performing T2-weighted sequences in the MRI evaluation of patients with acromegaly as an additional tool that can help to establish the correct diagnosis.

Identifiants

pubmed: 35512251
pii: 6580500
doi: 10.1210/clinem/dgac274
doi:

Substances chimiques

Growth Hormone-Releasing Hormone 9034-39-3

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e3313-e3320

Subventions

Organisme : Albert Beckers by the Fonds d'Investissment pour la Recherche
Organisme : Centre Hospitalier Universitaire de Liege
ID : 2018-2020

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Iulia Potorac (I)

Departments of Endocrinology, Centre Hospitalier de Liège, Université de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.

Jean-François Bonneville (JF)

Departments of Endocrinology, Centre Hospitalier de Liège, Université de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.
Medical Imaging, Centre Hospitalier de Liège, Université de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.

Adrian F Daly (AF)

Departments of Endocrinology, Centre Hospitalier de Liège, Université de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.

Wouter de Herder (W)

Department of Internal Medicine, Section of Endocrinology, Erasmus University Medical Center, 3015 GD, Rotterdam, The Netherlands.

Patricia Fainstein-Day (P)

Department of Endocrinology, Hospital Italiano de Buenos Aires, 1199, Buenos Aires, Argentina.

Philippe Chanson (P)

Université Paris-Saclay, Inserm, Physiologie et Physiopathologie Endocriniennes, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse HYPO, 94270 Le Kremlin-Bicêtre, France.

Marta Korbonits (M)

Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London E1 4NS, United Kingdom.

Fernando Cordido (F)

Department of Endocrinology, University Hospital A Coruña, 15006 A Coruña, Spain.

Elisa Baranski Lamback (E)

Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, 21941-617 Rio de Janeiro, Brazil.

Mohamed Abid (M)

Department of Endocrinology, Hedi Chaker Hospital, 3000 Sfax, Tunis.

Véronique Raverot (V)

Biochemistry Laboratory Department, Groupement Hospitalier Est, Hospices Civils de Lyon, 69002 Lyon, France.

Gerald Raverot (G)

Fédération d'Endocrinologie, Centre de Référence des Maladies Rares Hypophysaires HYPO, Groupement Hospitalier Est, Hospices Civils de Lyon, 69002 Lyon, France.

Emma Anda Apiñániz (E)

Department of Endocrinology and Nutrition, Complejo Hospitalario de Navarra, 31008 Pamplona, Spain.

Philippe Caron (P)

Service d'Endocrinologie et Maladies Métaboliques, Centre Hospitalier Universitaire de Toulouse, 31300 Toulouse, France.

Helene Du Boullay (H)

Department of Endocrinology, General Hospital of Chambéry, 73000 Chambéry, France.

Martin Bildingmaier (M)

Department for Endocrinology, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-University, 80539 Munich, Germany.

Marek Bolanowski (M)

Department of Endocrinology, Diabetes and Isotope Therapy, Wroclaw Medical University, 50-367 Wroclaw, Poland.

Marie Laloi-Michelin (M)

Department of Diabetes and Endocrinology, Lariboisière Hospital, 75010 Paris, France.

Francoise Borson-Chazot (F)

Hospices Civils de Lyon, Fédération d'Endocrinologie, Université Claude Bernard Lyon 1, 69002 Lyon, France.

Olivier Chabre (O)

Service d'Endocrinologie, Centre Hospitalier Universitaire de Grenoble, 38700 La Tronche, France.

Sophie Christin-Maitre (S)

Department of Endocrinology, Hôpital St Antoine, AP-HP, Sorbonne University, 75012 Paris, France.

Claire Briet (C)

Service d'endocrinologie, diabétologie et nutrition, CHU d'Angers, 49100 Angers, France.

Gonzalo Diaz-Soto (G)

Servicio de Endocrinología y Nutrición, Hospital Clínico Universitario de Valladolid, 47003 Valladolid, Spain.

Fabrice Bonneville (F)

Department of Neuroradiology, University Hospital Purpan, 31300 Toulouse, France.

Frederic Castinetti (F)

Department of Endocrinology, Aix Marseille Université, 13007 Marseille, France.

Mônica R Gadelha (MR)

Neuroendocrinology Research Center/Endocrinology Division, Medical School and Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, 21941-617 Rio de Janeiro, Brazil.

Nathalie Oliveira Santana (N)

Laboratório de Endocrinologia Celular e Molecular (LIM25), Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP 05403-000, Brasil.

Maria Stelmachowska-Banaś (M)

Department of Endocrinology, The Centre of Postgraduate Medical Education, 01-813 Warsaw, Poland.

Tomas Gudbjartsson (T)

Department of Cardiothoracic Surgery, Landspitali University Hospital, Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.

Roció Villar-Taibo (R)

Endocrinology and Nutrition Department, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain.

Taiba Zornitzki (T)

Diabetes, Endocrinology and Metabolic Disease Institute, Kaplan Medical Center, Hebrew University Medical School, Rehovot 76100, Israel.

Luaba Tshibanda (L)

Medical Imaging, Centre Hospitalier de Liège, Université de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.

Patrick Petrossians (P)

Departments of Endocrinology, Centre Hospitalier de Liège, Université de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.

Albert Beckers (A)

Departments of Endocrinology, Centre Hospitalier de Liège, Université de Liège, Domaine Universitaire du Sart Tilman, 4000 Liège, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH